Skip to main content

Pfizer Inc (PFE-N) Quote

Newsletters Subscribe Register My account My account AdChoices
Unchecking box will stop auto data updates
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 42.26
Day High 42.88
Open:42.86
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Latest
Inside the Market
Before the Bell: What every Canadian investor needs to know today
Subscriber content
Inside the Market
Tuesday’s analyst upgrades and downgrades
Subscriber content
U.S. Business
Pfizer plans to increase prices in U.S. on 41 medicines in January
Inside the Market
Before the Bell: What every Canadian investor needs to know today
Subscriber content
Inside the Market
Thursday’s analyst upgrades and downgrades
Subscriber content
number cruncher
A dividend prescription for yield-seeking investors
Subscriber content
Description
Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer healthcare products. Pfizer's Animal Health business unit discovers, develops and sells products for the prevention and treatment of diseases in livestock and companion animals. It sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, veterinarians, livestock producers, and grocery and convenience stores. Pfizer Inc. is headquartered in New York.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

View Earnings zacks

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

View Estimates zacks

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Download Report (PDF) Thomson Reuters

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Download Report (PDF) StockCalc

Latest Press Releases

More Stories
Ocular Inflammation Treatment Market is set to Grow US$ 500 Billion by 2024
Heraldkeeper - Wed Jan 16, 12:08PM CST
Heraldkeeper - CMTX
Wed Jan 16, 12:08PM CST
New York, January 16, 2019: The is expected to exceed more than US$ 500 Billion by 2024 at a CAGR of 6% in the given forecast period.
US FDA Accepts Regulatory Submissions for Review of Tafamidis to Treat Transthyretin Amyloid Cardiomyopathy
BusinessWire - Mon Jan 14, 7:00AM CST
BusinessWire - CMTX
Mon Jan 14, 7:00AM CST
Pfizer Inc. (NYSE: PFE) announced today that the US Food and Drug Administration (FDA) accepted for filing the company's New Drug Applications (NDAs) for tafamidis for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). Pfizer has submitted two NDAs based on two forms of tafamidis: meglumine salt and free acid. Tafamidis is the only product to complete a Phase 3 trial evaluating its efficacy, safety, and tolerability in patients with ATTR-CM, a rare, fatal, and underdiagnosed condition.(1,2)
Why Clinical Trial Advantages and Regulatory Process in EU may Hold Advantages Over the U.S.
PR Newswire - Wed Jan 9, 7:30AM CST
PR Newswire - CMTX
Wed Jan 9, 7:30AM CST
Financialnewsmedia.com News Commentary
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 40.42 +5.22% increase
on 12/26/18
Period Open:42.40
Price movement based on the high, low and last over the given period.
43.73 -2.74% decrease
on 12/31/18
 +0.13 (+0.31%) increase
since 12/18/18
3-Month 40.42 +5.22% increase
on 12/26/18
Period Open:44.00
Price movement based on the high, low and last over the given period.
46.47 -8.48% decrease
on 12/04/18
 -1.47 (-3.34%) decrease
since 10/18/18
52-Week 33.20 +28.10% increase
on 02/09/18
Period Open:36.99
Price movement based on the high, low and last over the given period.
46.47 -8.48% decrease
on 12/04/18
 +5.54 (+14.98%) increase
since 01/18/18

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2019.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

More stories below advertisement